150 results about "Neural cell" patented technology

The present disclosure provides materials and methods for delivery of a transgene to target cells. The regulatory elements, transgenes, and expression vectors are useful in, e.g., expressing a transgene in CNS cells that results in an improvement in at least one symptom related to a neurological disease or disorder, including epilepsy disorders, such as refractory epilepsy.

A Biological Neural Network (BNN) core unit comprising a neural cell culture, an input stimulation unit, an output readout unit may be controlled through its various life cycles to provide data processing functionality. An automation system comprising an environmental and chemical controller unit adapted to operate with the BNN stimulation and readout data interfaces facilitates the monitoring and adaptation of the BNN core unit parameters. Pre-processing and post-processing of the BNN interface signals may further facilitate the training and reinforcement learning by the BNN. Multiple BNN core units may also be assembled together as a stack. The proposed system provides a BNN Operating System as a core component for a wetware server to receive, process and transmit data for different client applications without exposing the BNN core unit components to the client user while requiring significantly less energy than conventional silicon-based hardware and software information processing for high-level cognitive computing tasks.

A Biological Neural Network (BNN) core unit comprising a neural cell culture, an input stimulation unit, an output readout unit may be controlled through its various life cycles to provide data processing functionality. An automation system comprising an environmental and chemical controller unit adapted to operate with the BNN stimulation and readout data interfaces facilitates the monitoring and adaptation of the BNN core unit parameters. Pre-processing and post-processing of the BNN interface signals may further facilitate the training and reinforcement learning by the BNN. Multiple BNN core units may also be assembled together as a stack. The proposed system provides a BNN Operating System as a core component for a wetware server to receive, process and transmit data for different client applications without exposing the BNN core unit components to the client user while requiring significantly less energy than conventional silicon-based hardware and software information processing for high-level cognitive computing tasks.

The present invention relates to the field of nerve cell labeling methods and related animal model technologies, and specifically to a promoter of a lgals3bpb gene and its application in constructing a zebrafish model. The application of the promoter of the lgals3bpb gene in constructing a zebrafish model comprises the following steps performed in sequence: obtaining the promoter of the lgals3bpb gene through a PCR reaction; constructing an expression vector regulated by the promoter of the lgals3bpb gene; transferring the expression vector into zebrafish fertilized eggs, and obtaining a stable genetically modified zebrafish strain through culture, screening and multi-generation hybridization. This technical solution can solve the technical problem of the prior art due to the lack of a zebrafish animal model capable of locating and operating microglia, and creates conditions for studying microglia, conducting disease mechanism research, drug screening and drug efficacy testing, and has good application prospects.

The present invention is directed to genetic manipulation of neural cells in the gyrencephalic fetal brain for developing treatment strategies for various neurodevelopmental disorders.

Described herein is a microphysiological system for models of disease. Specifically, induced pluripotent stem cells (iPSCs) and iPSC-derived cells, including those obtained from disease patients, are seeded onto microfluidic “chip” devices to study cellular development and disease pathogenesis. Herein, neurodegenerative disease modeling, including Parkinson's Disease (PD) is shown to reproduce key PD pathology in a vascularized human model that contains neurons relating to PD pathology. Such compositions and methods are used for research for PD biomarkers, patient screening for PD risk assessment, and therapeutic discovery and testing. A panel of biomarkers are generated through analysis of living PD-chips by neural activity, whole transcriptomic, proteomic, and metabolomic analysis, and functional enzyme tests of media and tissue. Introducing therapeutics through a vasculature channel, coupled with blood brain barrier penetration studies can be assessed for efficacy in the human neural cells present in the PD-Chip.

Described herein are techniques for identifying regions of substantia nigra reticulata (SNR) and regions of substantia nigra compact dorsal (SNCD) in histology images and quantifying a number of dopaminergic neural cells within the images. In some embodiments, an image of a section of a brain may be input into a first machine learning model to obtain a first segmentation map comprising pixel-wise labels indicative of whether a corresponding pixel in the image depicts a region of SNR or SNCD. In some embodiments, the image (and, optionally, the first segmentation map) may also be input to a second machine learning model trained to generate a second segmentation map comprising pixel-wise labels indicating whether a corresponding pixel of the image depicts a dopaminergic neural cell or neural background tissue. The number of cells within the image may be determined based on the second segmentation map.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

To provide oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons.SOLUTION: The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.SELECTED DRAWING: Figure 1

Disclosed herein are methods of treating ALS in a subject by administering to the subject a therapeutically effective amount of a composition comprising, for example, EV derived from nerve cells, such as neural progenitor cells. The EVs may be administered distally or peripherally to the CNS such that these EVs cross the blood-brain barrier and exert their therapeutic function in the CNS. The methods may reduce inflammation (e.g., NLRP3 inflammatory pathway signaling), reduce disease activity or progression, and / or improve motor or neurological performance, signs or symptoms associated with ALS, or survival in an ALS subject as compared to a control ALS subject. Also provided are methods of inhibiting necroptosis in a cell by contacting the cell with a therapeutically effective amount of a composition comprising EV.

The present invention relates to a method for producing a three-dimensional neuronal cell cluster, and a three-dimensional neuronal cell cluster produced thereby, wherein stem cells are differentiated into neuroepithelial cells, separated into individual cells, and then cultured in a three-dimensional re-aggregation mode by limiting the initial number of cells to a specific count of cells. According to the production method of the present invention, central necrosis is suppressed even during cultivation, and neural cell characteristics are expressed, whereby the method can be highly useful in various applications such as clinical and research fields and enables the production of micro-sized neural cell aggregates suitable for transplantation and injectable applications.

The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3):(1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGFβ family signal transduction pathway inhibiting substance and / or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state,(2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.

We provide a 3-dimensional configuration of an electrode array for neural cell stimulation designed to leverage migration of retinal cells into voids in the subretinal space. Walls surrounding each pixel align the electric field vertically, matching the orientation of bipolar cells in the retina, and thereby reduce the stimulation threshold. These walls also decouple the field penetration depth from the pixel width, enabling a decrease of the pixel size down to cellular dimensions. Inner retinal cells migrate into the electrode cavities, which enables very efficient stimulation. Due to 1-dimensional alignment of electric field along the cavities, stimulation threshold current density does not increase significantly with the reduced pixel size, unlike the quadratic increase seen with planar arrays.

The invention relates to the technical field of nerve cell marking and regulation and control, in particular to a nerve cell living body selective protein modification probe capable of penetrating a blood brain barrier and application of the nerve cell living body selective protein modification probe. The protein body part specifically targets a living glutamic acid energetic neuron cell membrane, the protein body part and / or a modified part thereof can regulate and control the function of the glutamic acid energetic neuron, and a coding sequence of the protein body part comprises a sequence as shown in SEQ ID NO: 1 or a sequence having at least 85% identity with the SEQ ID NO: 1. The protein modified probe provided by the invention provides a new feasible thought for developing in-vivo nerve cell selective markers and regulation tools which are non-gene transfection of blood brain barrier penetration, are high in biological safety, are more stable and are easy to obtain and have nerve cell specific type selectivity.

Porous electrically conductive graphene / carbon nanofiber bio-scaffolds can be fabricated having a Youngs modulus and electrical conductivity that both match typical values for brain tissue. Such scaffolds have been tested and found to provide improved differentiation of stem cells into functional neural cells relative to conventional scaffolds. In preferred embodiments, neural cell differentiation in conductive graphene / carbon nanofiber scaffolds is promoted by an applied electrical stimulus.

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.

The application belongs to the technical field of biological medical materials, and discloses a polydopamine modified modified nano-graphyne and a preparation method and application thereof. In the method, the polydopamine coating is combined with the nano-graphyne for the first time to construct a GDY@PDA composite system, and the core defects of the blocky graphyne, such as easy agglomeration, poor water solubility and insufficient biocompatibility, are solved. The graphyne-based material is applied to the near-infrared two-region photothermal regulation of neural cell calcium influx for the first time, the calcium ion channel is activated through the local thermal effect of the material, and precise, remote and reversible calcium influx regulation is realized; the limitation that the traditional biocompatibility modification is easy to fall off and difficult to functionalize is broken through, the polydopamine modification makes the material have both photothermal efficiency and biological safety, and the application of the graphyne in the treatment of neural diseases (such as neural cell injury repair) is expanded.

The invention relates to the technical field of nerve cell differentiation, and discloses a culture medium for promoting neural differentiation of SH-SY5Y cells. The culture medium disclosed by the invention is prepared from the following components: tazarotene (tazarotene) and a basic culture medium. The culture medium can promote SH-SY5Y cells to present neuron-like differentiation within 5 days, significantly improves the length of neurite and the expression level of neuron markers, and is low in cytotoxicity. The invention provides an efficient, safe and standardized new tool for neural disease in-vitro model construction, drug screening and mechanism research.

The application discloses a high-channel clinical microelectrode array intelligent brain function positioning system and method, and belongs to the fields of electronic information and clinical disease diagnosis and treatment technologies. The system comprises a microelectrode array implanted in the brain, a signal processing and transmission unit and a signal identification unit. The microelectrode array adopts a multi-channel design, can synchronously detect neural electrophysiological signals and transmitter chemical signals of different depths and directions, and has a resolution of a single cell level. The signal processing and transmission unit is responsible for signal acquisition, amplification and transmission, and applies electrical stimulation; the signal identification unit performs real-time processing on the signals through a convolutional neural network algorithm, quickly identifies target nuclei, and realizes accurate positioning. The application can realize real-time monitoring of neural cell discharges and transmitter releases at different depths and different directions, and can realize rapid and accurate target positioning with the aid of advanced intelligent algorithms, thereby providing a more reliable basis for DBS surgery.

A method for assessing differentiation potential of cells in a culture broth in the differentiation of pluripotent stem cells into neural cells of the midbrain floor plate region, comprising: measuring a concentration of NT-3 in a culture supernatant in a culture broth obtained by culturing the pluripotent stem cells in a medium containing an inducer of differentiation into the neural cells of the midbrain floor plate region; comparing the measured concentration of NT-3 with a reference concentration; and when the concentration of NT-3 is equal to or more than the reference concentration, assessing the cells in the culture broth as capable of differentiating into the neural cells of the midbrain floor plate region, wherein the culture supernatant is a culture supernatant collected from the culture broth at any time from 48 hours to 240 hours after the start of culture of the pluripotent stem cells.

A method of activating a piezoelectric neuroconduit guide scaffold including a plurality of aligned piezoelectric polymer nanofibers, the method including mechanically stimulating the piezoelectric neuroconduit guide scaffold with hydro-acoustic waves or shockwaves to remotely activate a piezoelectric effect of the nanofibrous scaffolds that induces a mechano-electrical stimulus on neural cells cultured on the scaffold, wherein the mechano-electrical stimulus promotes nerve fiber outgrowth from the neuronal cells. Some aspects relate to seeding individual components of neural tissues on the piezoelectric neuroconduit guide scaffold, wherein the hydro-acoustic stimulation induces neural tissue formation. In other aspects, the piezoelectric neuroconduit guide scaffold is implanted in a damaged neural tissue, wherein stimulating the piezoelectric neuroconduit guide scaffold by the application of shockwaves promotes nerve fiber outgrowth that bridges a nerve gap to induce nerve regeneration or reinnervation of the damaged neural tissue.

The invention relates to a method for efficiently producing a stomach-like organ with a self-organizing asymmetric pattern, and belongs to the technical field of organ culture. The invention provides a new application of the nerve cell precursor cell, the nerve cell precursor cell can promote posterior anterior intestine sphere differentiation to obtain a stomach organ with a self-organizing stomach fundus-antral pattern (free-antral pattern) characteristic, the structure and the cell lineage of the stomach organ are similar to those of an in-vivo stomach organ, and the stomach organ has better fidelity. The method provided by the invention is suitable for various human pluripotent stem cells, and can be used for efficiently producing asymmetric stomach organs.

The invention belongs to the technical field of biomedical materials, and discloses polydopamine modified nano graphdiyne as well as a preparation method and application thereof. According to the method, a polydopamine coating is combined with nano graphdiyne for the first time, a GDY and PDA composite system is constructed, and the core defects that blocky graphdiyne is prone to agglomeration, poor in water solubility and insufficient in biocompatibility are overcome. The graphdiynyl material is applied to near-infrared two-region photo-thermal regulation and control of nerve cell calcium internal flow for the first time, a calcium ion channel is activated through the local warming effect of the material, and accurate, remote and reversible calcium internal flow regulation and control are achieved; the limitation that traditional biocompatibility modification is easy to fall off and difficult to functionalize is broken through, the material has photo-thermal efficiency and biological safety through polydopamine modification, and the application of graphdiyne in nerve disease treatment (such as nerve cell damage repair) is expanded.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP 1 A3 and / or Tubulin.

The present invention relates to a neuroprotective drug for Parkinson's disease and its application, and relates to the field of biomedicine technology. + Treatment of SH-SY5Y neural cell line to establish MPP + In a cell model of PD induced by PD, N-[5-acetyl-1-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-1H-pyrrol-3-yl]acetamide was used for intervention. Cell viability, cytotoxicity and mitochondrial membrane potential were detected after intervention. It was found that N-[5-acetyl-1-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-1H-pyrrol-3-yl]acetamide could reduce MPP + Induced SH‑SY5Y cell damage and cytotoxicity, improved MPP in SH‑SY5Y cells + Caused by mitochondrial dysfunction.

The invention discloses an effect of TMEM159 in preparation of a medicine for treating cerebral ischemia reperfusion injury. According to the application disclosed by the invention, molecular biology experiments find that the expression of the TMEM159 in cerebral ischemia reperfusion brain tissues is reduced, and single cell sequencing data in a public database shows that the TMEM159 is mainly expressed in neuronal cells; an AAV9-mediated nerve cell specific TMEM159 overexpression adeno-associated virus vector is further constructed to verify the application of TMEM159 as a treatment target, and the result shows that the TMEM159 overexpression can reduce the cerebral infarction area caused by cerebral ischemia and reduce the cell apoptosis level; therefore, the invention provides a new therapeutic target and medicine for the cerebral ischemia disease, and the TMEM159 overexpression adeno-associated virus provided by the invention has the advantages of long-term expression, low toxicity, low immunogenicity, high tissue specificity and the like, and has good application prospects and transformation values.

The present invention relates to a method for producing neuronal cells from dedifferentiated adipocytes derived from a mammal, the method comprising a step for culturing dedifferentiated adipocytes derived from a mammal using a medium that contains a basic fibroblast growth factor (bFGF), retinoic acid, and a neuronal differentiation inducer, but does not substantially contain an epigenetic inhibitor.

A method of promoting compensatory plasticity of spared neural cells after a neural injury includes contacting the spared neural cells with an effective amount of a therapeutic agent comprising a therapeutic peptide, wherein the therapeutic peptide comprises an amino acid sequence with at least 70% identity to SEQ ID NO:32.

The present invention relates to a method for culturing neural cells and to a neural organoid for use in medical or diagnostic treatment.

The present invention provides a method for inducing the differentiation of pluripotent stem cells into dopaminergic neural cells or a method for producing a cell group containing dopaminergic neural cells from pluripotent stem cells, each of the methods comprising: (1) bringing the pluripotent stem cells into contact with a TGFβ inhibitor, a BMP inhibitor, and / or a GSK3β inhibitor; and (2) expressing Ascl1 gene in the pluripotent stem cells.